FDA rejected review of Moderna's mRNA flu vaccine despite positive trial results
Experts express concerns about Trump administration's approach to vaccine development
The rejection has sent alarm bells through the scientific community
mRNA technology has shown significant promise in vaccine development following COVID-19 success
📖 Full Retelling
The U.S. Food and Drug Administration recently announced its decision not to review Moderna's mRNA flu vaccine, despite late-stage clinical trials demonstrating both safety and effectiveness, raising concerns among industry experts and public health officials about the Trump administration's approach to vaccine development and approval processes. The rejection comes as mRNA technology has shown significant promise in developing next-generation vaccines, following its successful application in COVID-19 vaccines that helped mitigate the global pandemic. Many epidemiologists and pharmaceutical professionals view this decision as potentially undermining scientific progress in vaccine innovation, particularly as seasonal influenza continues to pose substantial health risks worldwide. Michael Osterholm, a prominent epidemiologist, expressed particular alarm, stating that the rejection 'sends chills' through the scientific community and may signal a troubling shift away from evidence-based medicine in vaccine policy. The decision has sparked debate about political influence in regulatory processes and could have far-reaching implications for future vaccine development, not only for influenza but potentially for other infectious diseases as well.
🏷️ Themes
Vaccine Policy, Public Health, Scientific Regulation
Moderna, Inc. ( mə-DUR-nə) is an American pharmaceutical and biotechnology company based in Cambridge, Massachusetts, that focuses on RNA therapeutics, primarily mRNA vaccines. These vaccines use a copy of a molecule called messenger RNA (mRNA) to carry instructions for proteins to produce an immune...
Influenza vaccines, colloquially known as flu shots or flu jab, are vaccines that protect against infection by influenza viruses. New versions of the vaccines are developed twice a year, as the influenza virus rapidly changes. While their effectiveness varies from year to year, most provide modest t...
The U.S. Food and Drug Administration announced recently that it will not review Moderna's mRNA flu vaccine, despite late-stage trials showing it was safe and effective. The rejection has many in and outside the industry concerned about the Trump administration's approach to vaccine development and recommendations. Amna Nawaz discussed more with Michael Osterholm.
